We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+15.35%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$370M
AUM Growth
+$95.8M
(+35%)
Cap. Flow
+$73.9M
Cap. Flow
% of AUM
19.94%
Top 10 Holdings %
Top 10 Hldgs %
36.28%
Holding
91
New
23
Increased
27
Reduced
13
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$24.7M |
| 2 |
CVS Health
CVS
|
+$13.7M |
| 3 |
GSK
GSK
|
+$10.5M |
| 4 |
Gilead Sciences
GILD
|
+$9.94M |
| 5 |
Globus Medical
GMED
|
+$9.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$9.96M |
| 2 |
Cigna
CI
|
+$9.92M |
| 3 |
Cardinal Health
CAH
|
+$9.32M |
| 4 |
CELG
Celgene Corp
CELG
|
+$6.56M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$6.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.51% |
| 2 | Industrials | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Cardinal Health
CAH
$54.4B
| – | – |
-209,009
| Closed | -$9.32M |
|
|
77
Cigna
CI
$74.6B
| – | – |
-52,216
| Closed | -$9.92M |
|
|
78
Cencora
COR
$60.8B
| – | – |
-133,934
| Closed | -$9.96M |
|
79
Establishment Labs
ESTA
$2.82B
| – | – |
-52,701
| Closed | -$1.45M |
|
80
Kura Oncology
KURA
$805M
| – | – |
-144,411
| Closed | -$2.03M |
|
81
Neurocrine Biosciences
NBIX
$16.9B
| – | – |
-69,000
| Closed | -$4.93M |
|
82
Philips
PHG
$25.6B
| – | – |
-64,415
| Closed | -$1.76M |
|
|
PINC
83
DELISTED
Premier
PINC
| – | – |
-134,412
| Closed | -$5.02M |
|
84
Veracyte
VCYT
$3.65B
| – | – |
-70,199
| Closed | -$883K |
|
85
Viatris
VTRS
$20.4B
| – | – |
-187,175
| Closed | -$5.13M |
|
86
Dentsply Sirona
XRAY
$2.81B
| – | – |
-65,666
| Closed | -$2.44M |
|
|
TMDI
87
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
| – | – |
-445,680
| Closed | -$544K |
|
|
IVC
88
DELISTED
Invacare Corporation
IVC
| – | – |
-247,196
| Closed | -$1.06M |
|
|
CFMS
89
DELISTED
Conformis, Inc. Common Stock
CFMS
| – | – |
-44,876
| Closed | -$402K |
|
|
IMMU
90
DELISTED
Immunomedics Inc
IMMU
| – | – |
-25,900
| Closed | -$370K |
|
|
CELG
91
DELISTED
Celgene Corp
CELG
| – | – |
-102,390
| Closed | -$6.56M |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Sio Capital Management held 91 positions worth $370M, up 35% from $275M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management deployed $73.9M of net new capital in Q1 2019, opening 23 new positions and adding to 27 existing holdings. Its largest new stake was Biogen: 78,596 shares worth $18.6M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 91% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $6.31M trimmed.
- Sio Capital Management's largest Q1 2019 buy was Biogen: 78,596 shares worth $18.6M.
- Sio Capital Management added most to CVS Health in Q1 2019, an estimated $13.7M increase.
- Sio Capital Management's biggest Q1 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $6.31M.
- Sio Capital Management fully exited Cencora in Q1 2019, selling an estimated $9.96M.
- Sio Capital Management's ten largest holdings make up 36% of its $370M portfolio in Q1 2019.
- Sio Capital Management opened 23 new positions and closed 22 in Q1 2019.
- Sio Capital Management's portfolio value rose 35% quarter-over-quarter to $370M.
Based on Sio Capital Management's 13F filing for Q1 2019, filed 15 May 2019.